Individuals Discontinuing Slimming Jabs Put On Pounds at a Quadrupled Rate Compared to People Using Diet and Exercise

Fresh analysis indicates that individuals who stop using new weight-loss injections like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who halt traditional diet and exercise plans.

Findings released in a leading health publication shows that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.

"Individuals purchasing these treatments must be aware of the danger of fast weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.

That rate of regain implies a reversion to pre-treatment mass within about one and a half years.

Weighing Treatments

The study, which examined 37 of studies involving thousands of patients, contrasted the results of the injectable medications with older methods.

Scientists emphasize that people who lose weight through lifestyle changes alone generally have a slower weight regain—approximately 100 grams monthly—post-intervention.

Understanding the Rapid Regain

Doctors believe the mode of action of the injections is key to understanding the heightened weight return.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating far more likely."

A Lifelong Condition?

Medical guidelines advise the injections for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.

A number of clinicians argue that, given the significant potential of relapse, the therapy is often life-long.

This view is reinforced by drug manufacturers, who state that the findings "highlight the persistent character of obesity," similar to managing diseases like high blood pressure.

Patient Experiences

People who have come off the medication report a powerful return of cravings.

"It was like a trigger that goes on and I was suddenly starving," recalled one woman.

The struggle is worsened if users have not developed lasting lifestyle or habit modifications during treatment.

Growing Adoption

Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with desire being substantial.

• Adoption is greater among females compared to males.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion access the medications through private healthcare rather than the NHS.

Finally, experts caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and maintained weight loss relies on combined lifestyle management.